NCT01553617 - VolulyteTM in Cardiac Surgery | Biotech Hunter

Enrollment

133

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions

Heart; Dysfunction Postoperative, Cardiac Surgery

Interventions

DRUG

6% hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (VolulyteTM)

Study drug will be given as part of priming of the ECC and for volume therapy up to the maximum dosage of 50 mL/kg body weight/day

DRUG

Human serum albumin

Control drug will be given as part of priming of the ECC and for volume therapy up to the maximum dosage of 50 mL/kg body weight/day

Trial Locations (5)

Vancouver General Hospital, Vancouver

Queen Elizabeth II Health Sciences Centre, Halifax

London Health Sciences Centre, London

St. Michael's Hospital, Toronto

Toronto General Hospital, Toronto